TAP Begins New Five Year Collaboration with Top Regenerative Medicine Centre
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The Automation Partnership (TAP) announces that its collaboration with leading translational research group, the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine at Loughborough University is to continue into a second five year phase.
This follows the recent announcement by Prime Minister, Gordon Brown and Lord Mandelson, UK Secretary of State, Department for Business, Innovation and Skills of a £5.33 million grant to the centre.
TAP’s new five year partnership with EPSRC Centre for Innovative Manufacturing in Regenerative Medicine will mean the further development and testing of its CompacT CellBase™ system for culturing clinically applicable stem cells in a Good Manufacturing Practice (GMP) environment.
Additionally, the funding will allow TAP to begin new research with the centre to develop ambr™, TAP’s advanced microscale bioreactor that mimics the characteristics of classical bioreactors. This project will enable the centre to explore the use of alternative technology platforms to ensure high quality stem cell therapies.
This new collaboration is a continuation of the work TAP began as part of the remedi (regenerative medicine – a new industry) EPSRC Grand Challenge consortium in 2005 and has contributed to remedi achieving three world firsts in automated cell culture, including production in a CompacT CellBase of a clinical grade neuronal stem cell line.
This follows the recent announcement by Prime Minister, Gordon Brown and Lord Mandelson, UK Secretary of State, Department for Business, Innovation and Skills of a £5.33 million grant to the centre.
TAP’s new five year partnership with EPSRC Centre for Innovative Manufacturing in Regenerative Medicine will mean the further development and testing of its CompacT CellBase™ system for culturing clinically applicable stem cells in a Good Manufacturing Practice (GMP) environment.
Additionally, the funding will allow TAP to begin new research with the centre to develop ambr™, TAP’s advanced microscale bioreactor that mimics the characteristics of classical bioreactors. This project will enable the centre to explore the use of alternative technology platforms to ensure high quality stem cell therapies.
This new collaboration is a continuation of the work TAP began as part of the remedi (regenerative medicine – a new industry) EPSRC Grand Challenge consortium in 2005 and has contributed to remedi achieving three world firsts in automated cell culture, including production in a CompacT CellBase of a clinical grade neuronal stem cell line.
